NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation phase I trial (Study 1100)

Pour en savoir plus sur nos technologies, nos collaborations, nos essais cliniques ou tout autre sujet, contactez-nous.